Drug Trial Radar · NCT07789015
A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
270
Planned (sponsor's estimate)
Start
Dec 14, 2026
Primary completion
Mar 21, 2030
Study completion Apr 4, 2030
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Aug 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults aged 18 and older who have a condition known as active idiopathic inflammatory myopathy (IIM) or myositis. People can participate if they have a specific type of myositis. The purpose of this study is to find out whether a medicine called nerandomilast improves IIM symptoms. Participants are put into 2 groups randomly, which means by chance. One group takes nerandomilast tablets and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Participants take nerandomilast or placebo twice a day for 1 year. Participants are in the study for about 1 year and 2 months. During this time, they visit the study site at least 16 times. During this time, doctors regularly check the participant's health, IIM symptoms, and take note of any unwanted effects. Participants fill in questionnaires about their IIM symptoms and how IIM impacts their quality of life. The results are compared between the 2 groups to see whether the treatment works.
Conditions
- Idiopathic Inflammatory Myopathies
Interventions
PlaceboDrug
Placebo-matching nerandomilast
NerandomilastDrug
Nerandomilast
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total improvement score (TIS) score (continuous) at Week 52Time frame: At Week 52.
Locations
160 sites in 26 countries. Site status is shown where the registry gives one.
Mayo Clinic
Scottsdale, Arizona
University of California Irvine
Irvine, California
University of California Los Angeles
Los Angeles, California
University of California San Francisco
San Francisco, California
University of Colorado Denver
Aurora, Colorado
The University of Chicago Medical Center
Chicago, Illinois
Kansas University Medical Center
Fairway, Kansas
Johns Hopkins Hospital
Baltimore, Maryland
Brigham and Women's Hospital
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Mayo Clinic, Rochester
Rochester, Minnesota
Washington University School of Medicine
St Louis, Missouri
Northwell Health
Great Neck, New York
Cleveland Clinic
Cleveland, Ohio
Paramount Medical Research and Consulting
Middleburg Heights, Ohio
Oregon Health & Sciences University
Portland, Oregon
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
West Tennessee Research Institute
Jackson, Tennessee
Helios CR, Inc - Dallas
Dallas, Texas
Nerve and Muscle Center of Texas
Houston, Texas
The University of Texas Health Science Center at Houston
Houston, Texas
Bioclinic Research
C.a.b.a, Argentina
Centro Argentino de Investigacion (CADI)-Diagnostico Medico
CABA, Argentina
Instituto de Investigacion Clinica TyT
CABA, Argentina
Instituto Medico Especializado
Capital Federal, Argentina
Framingham Centro Medico
La Plata, Argentina
Instituto Medico CER
Quilmes, Argentina
Sanatorio de la Mujer
Rosario, Argentina
Centro de Investigaciones Medicas Tucuman
San Miguel de Tucumán, Argentina
Alto Dorrego Consultorios
Villa Nueva, Argentina
Campbelltown Hospital
Campbelltown, New South Wales, Australia
Wollongong Hospital
Wollongong, New South Wales, Australia
Austin Health
Ivanhoe, Victoria, Australia
Perron Institute
Nedlands, Western Australia, Australia
Universitair Ziekenhuis Gent
Ghent, Belgium
Universitair Ziekenhuis Brussel
Jette, Belgium
UZ Leuven
Leuven, Belgium
Centre Hospitalier Universitaire de Liège
Liège, Belgium
Showing 40 of 160 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.